Author(s)

Jian Huang^1,2

Affiliation(s)

¹Department of Gland Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China.

²Baise Key Laboratory of Molecular Pathology in Tumors.

Corresponding Author

Jian Huang

ABSTRACT

Breast cancer surgery treatment has a century of development from extended radical mastectomy to modified radical mastectomy and then to breast-conserving surgery. Breast cancer surgery tends to be more and more minimally invasive. Axillary surgery is an important part of breast cancer surgery. Sentinel lymph node biopsy (SLNB) is a common surgical procedure, and axillary lymph node dissection (ALND) is the most common choice for patients with positive sentinel lymph nodes. However, ALND has many sequelae for breast cancer patients, such as postoperative lymphedema, abnormal limb sensation and movement, etc. In the past decade, evidence has shown that it is feasible to avoid ALND in breast cancer with positive sentinel lymph nodes. Some scholars have studied that SLNB combined with axillary radiotherapy is equivalent to ALND. In short, axillary surgery is increasingly tending to be minimally invasive and narrow in scope. This study aims to explore the transformation and future development direction of axillary surgery for breast cancer.

KEYWORDS

Breast cancer; Axillary surgery; SLNB; ALND

CITE THIS PAPER

Jian Huang. The transformation of axillary surgery for breast cancer. Journal of Pharmaceutical and Medical Research. 2024, 6(2): 23-29. DOI: 10.61784/jpmr3001.

REFERENCES

[1] Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HMC, Wolmark N. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. The Lancet Oncology. 2010, 11: 927-933. DOI: 10.1016/s1470-2045(10)70207-2

[2] Giuliano AE,Ballman KV, McCall L,Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017, 318: 918-926. DOI: 10.1001/jama.2017.11470

[3] Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham DL, Deutsch M, Montague E, Margolese R, Foster R. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med. 1985, 312: 674-681. DOI: 10.1056/NEJM198503143121102

[4] Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002, 347: 567-575. DOI: 10.1056/NEJMoa020128

[5] Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiotocalization of the sentinel lymph node in breast cancer using a gamma probe. Surgical Oncology. 1993, 2: 335- 340.

[6] Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006, 98: 599-609. DOI: 10.1093/jnci/djj158

[7] Lyman GH, Giuliano AE, Somerfield MR, Benson AB, 3rd, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS, 3rd, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP, American Society of Clinical O. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2015, 23: 7703-7720. DOI: 10.1200/JCO.2005.08.001

[8] Riedel F, Heil J, Golatta M, Schaefgen B, Hug S, Schott S, Rom J, Schuetz F, Sohn C, Hennigs A. Changes of breast and axillary surgery patterns in patients with primary breast cancer during the past decade. Arch Gynecol Obstet. 2019, 299: 1043-1053. DOI: 10.1007/s00404-018-4982-3

[9] Bonneau C, Bendifallah S, Reyal F, Rossi L, Rouzier R. Association of the number of sentinel lymph nodes harvested with survival in breast cancer. Eur J Surg Oncol. 2015, 41: 52-58. DOI: 10.1016/j.ejso.2014.11.004

[10] Goyal A, Newcombe RG, Chhabra A, Mansel RE, Group AT. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer--results of the ALMANAC validation phase. Breast Cancer Res Treat. 2006, 99: 203-208. DOI: 10.1007/s10549-006-9192-1

[11] Chinese Anti-Cancer Association Breast Cancer Diagnosis and Treatment Guidelines and Standards (2019 Edition). Chinese Journal of Cancer. 2019, 29: 609-680.

[12] Bourre JC, Payan R, Collomb D, Gallazzini-Crepin C, Calizzano A, Desruet MD, Pasquier D, Bolla M, Fagret D, Vuillez JP. Can the sentinel lymph node technique affect decisions to offer internal mammary chain irradiation? Eur J Nucl Med Mol Imaging. 2009, 36: 758-764. DOI: 10.1007/s00259-008-1034-4

[13] Estourgie SH, Tanis PJ, Nieweg OE, Valdes Olmos RA, Rutgers EJ, Kroon BB. Should the hunt for internal mammary chain sentinel nodes begin? An evaluation of 150 breast cancer patients. Ann Surg Oncol. 2003, 10: 935-941. DOI: 10.1245/aso.2003.02.015

[14] Postma EL, van Wieringen S, Hobbelink MG, Verkooijen HM, van den Bongard HJ, Borel Rinkes IH, Witkamp AJ. Sentinel lymph node biopsy of the internal mammary chain in breast cancer. Breast Cancer Res Treat. 2012, 134: 735-741. DOI: 10.1007/s10549-012-2086-5

[15] Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O, Mastropasqua MG, Mazzarol G, Massarut S, Garbay J-R, Zgajnar J, Galatius H, Recalcati A, Littlejohn D, Bamert M, Colleoni M, Price KN, Regan MM, Goldhirsch A, Coates AS, Gelber RD, Veronesi U. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. The Lancet Oncology. 2013, 14: 297-305. DOI: 10.1016/s1470-2045(13)70035-4

[16] Sola M, Alberro JA, Fraile M, Santesteban P, Ramos M, Fabregas R, Moral A, Ballester B, Vidal S. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol. 2013, 20: 120-127. DOI: 10.1245/s10434-012-2569-y

[17] Verheuvel NC, Voogd AC, Tjan-Heijnen VC, Roumen RM. Potential impact of application of Z0011 derived criteria to omit axillary lymph node dissection in node positive breast cancer patients. Eur J Surg Oncol. 2016, 42: 1162-1168. DOI: 10.1016/j.ejso.2016.05.007

[18] Dixon JM, Cartlidge CWJ. Twenty-five years of change in the management of the axilla in breast cancer. Breast J. 2020, 26: 22-26. DOI: 10.1111/tbj.13720

[19] Henke G, Knauer M, Ribi K, Hayoz S, Gerard MA, Ruhstaller T, Zwahlen DR, Muenst S, Ackerknecht M, Hawle H, Fitzal F, Gnant M, Matrai Z, Ballardini B, Gyr A, Kurzeder C, Weber WP. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. Trials. 2018, 19: 667. DOI: 10.1186/s13063-018-3021-9

[20] Belkacemi Y, Allab-Pan Q, Bigorie V, Khodari W, Beaussart P, Totobenazara JL, Mege JP, Caillet P, Pigneur F, Dao TH, Salmon R, Calitchi E, Bosc R. The standard tangential fields used for breast irradiation do not allow optimal coverage and dose distribution in axillary levels I-II and the sentinel node area. Ann Oncol. 2013, 24: 2023-2028. DOI: 10.1093/annonc/mdt151

[21] Kataria T, Bisht SS, Gupta D, Goyal S, Jassal K, Abhishek A, Sharma K, Pareek P, Kumar V, Jain S, Tayal M, Karthikeyan N. Incidental radiation to axilla in early breast cancer treated with intensity modulated tangents and comparison with conventional and 3D conformal tangents. Breast. 2013, 22: 1125-1129. DOI: 10.1016/j.breast.2013.07.054

[22] van Wely BJ, Teerenstra S, Schinagl DA, Aufenacker TJ, de Wilt JH, Strobbe LJ. Systematic review of the effect of external beam radiation therapy to the breast on axillary recurrence after negative sentinel lymph node biopsy. Br J Surg. 2011, 98: 326-333. DOI: 10.1002/bjs.7360

[23] Jagsi R, Chadha M, Moni J, Ballman K, Laurie F, Buchholz TA, Giuliano A, Haffty BG. Radiation field design in the ACOSOG Z0011 (Alliance) Trial. J Clin Oncol. 2014, 32: 3600-3606. DOI: 10.1200/JCO.2014.56.5838

[24] Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJH, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JHG, Orzalesi L, Bouma WH, van der Mijle HCJ, Nieuwenhuijzen GAP, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JWS, Belkacemi Y, Petignat P, Schinagl DAX, Coens C, Messina CGM, Bogaerts J, Rutgers EJT. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014, 15: 1303-1310. DOI: 10.1016/S1470-2045(14)70460-7

[25] Savolt A, Peley G, Polgar C, Udvarhelyi N, Rubovszky G, Kovacs E, Gyorffy B, Kasler M, Matrai Z. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017, 43: 672-679. DOI: 10.1016/j.ejso.2016.12.011

[26] Bi Z, Liu J, Chen P, Liu Y, Zhao T, Wang C, Zhang Z, Sun X, Qiu P, Cong B, Song X, Wang Y. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla. Breast Cancer. 2019, 26: 373-377. DOI: 10.1007/s12282-018-00934-3

[27] van Nijnatten TJA, Schipper RJ, Lobbes MBI, Nelemans PJ, Beets-Tan RGH, Smidt ML. The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: A systematic review and meta-analysis. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2015, 41: 1278-1287. DOI: 10.1016/j.ejso.2015.07.020

[28] Hunt KK, Yi M, Mittendorf EA, Guerrero C, Babiera GV, Bedrosian I, Hwang RF, Kuerer HM, Ross MI, Meric-Bernstam F. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009, 250: 558-566. DOI: 10.1097/SLA.0b013e3181b8fd5e

[29] Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006, 93: 539-546. DOI: 10.1002/bjs.5209

[30] Lyman GH, Somerfield MR, Giuliano AE. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: 2016 American Society of Clinical Oncology Clinical Practice Guideline Update Summary. J Oncol Pract. 2017, 13: 196-198. DOI: 10.1200/JOP.2016.019992

[31] Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Kuerer HM, Bowling M, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Le-Petross HT, Haffty BG, Buchholz TA, Nelson H, Hunt KK, Alliance for Clinical Trials in O. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013, 310: 1455-1461. DOI: 10.1001/jama.2013.278932

[32] Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, Lebeau A, Liedtke C,Minckwitz Gv, Nekljudova V, Schmatloch S, Schrenk P, Staebler A, Untch M. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. The Lancet Oncology. 2013, 14: 609-618. DOI: 10.1016/s1470-2045(13)70166-9

[33] Niebling MG, Pleijhuis RG, Bastiaannet E, Brouwers AH, van Dam GM, Hoekstra HJ. A systematic review and meta-analyses of sentinel lymph node identification in breast cancer and melanoma, a plea for tracer mapping. Eur J Surg Oncol. 2016, 42: 466-473. DOI: 10.1016/j.ejso.2015.12.007

[34] Caudle AS, Yang WT, Mittendorf EA, Black DM, Hwang R, Hobbs B, Hunt KK, Krishnamurthy S, Kuerer HM. Selective Surgical Localization of Axillary Lymph Nodes Containing Metastases in Patients With Breast Cancer. JAMA Surgery. 2015, 150. DOI: 10.1001/jamasurg.2014.1086

[35] Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I,Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE, Shaitelman SF, Chavez-MacGregor M, Smith BD, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Kuerer HM. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol. 2016, 34: 1072-1078. DOI: 10.1200/JCO.2015.64.0094

[36] Gentilini O, Botteri E, Dadda P, Sangalli C, Boccardo C, Peradze N, Ghisini R, Galimberti V, Veronesi P, Luini A, Cassano E, Viale G, Veronesi U. Physical function of the upper limb after breast cancer surgery. Results from the SOUND (Sentinel node vs. Observation after axillary Ultra-souND) trial. Eur J Surg Oncol. 2016, 42: 685-689. DOI: 10.1016/j.ejso.2016.01.020